Final step of B-cell differentiation into plasmablasts; the right time to activate plasma cell PIM2 kinase.
B cell differentiation
ER stress
PIM2
Plasma cell
Journal
Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
16
01
2023
revised:
13
05
2023
accepted:
16
05
2023
medline:
29
5
2023
pubmed:
20
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
The differentiation of B cells into antibody-secreting plasma cells is a complex process that involves extensive changes in morphology, lifespan, and cellular metabolism to support the high rates of antibody production. During the final stage of differentiation, B cells undergo significant expansion of their endoplasmic reticulum and mitochondria, which induces cellular stress and may lead to cell death in absence of effective inhibition of the apoptotic pathway. These changes are tightly regulated at transcriptional and epigenetic levels, as well as at post-translational level, with protein modifications playing a critical role in the process of cellular modification and adaptation. Our recent research has highlighted the pivotal role of the serine/threonine kinase PIM2 in B cell differentiation, from commitment stage to plasmablast and maintenance of expression in mature plasma cells. PIM2 has been shown to promote cell cycle progression during the final stage of differentiation and to inhibit Caspase 3 activation, raising the threshold for apoptosis. In this review, we examine the key molecular mechanisms controlled by PIM2 that contribute to plasma cell development and maintenance.
Identifiants
pubmed: 37207916
pii: S0165-2478(23)00076-7
doi: 10.1016/j.imlet.2023.05.006
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-50Informations de copyright
Copyright © 2023 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.